Switch to:
Also traded in: Germany, Israel, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 3.09
OPK's Cash to Debt is ranked higher than
50% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. OPK: 3.09 )
Ranked among companies with meaningful Cash to Debt only.
OPK' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: 20.9 Max: No Debt
Current: 3.09
Equity to Asset 0.73
OPK's Equity to Asset is ranked higher than
67% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OPK: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
OPK' s Equity to Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.67 Max: 0.96
Current: 0.73
-0.41
0.96
F-Score: 5
Z-Score: 4.13
M-Score: 5.03
WACC vs ROIC
15.56%
-1.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -1.44
OPK's Operating margin (%) is ranked lower than
76% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.87 vs. OPK: -1.44 )
Ranked among companies with meaningful Operating margin (%) only.
OPK' s Operating margin (%) Range Over the Past 10 Years
Min: -31624.44  Med: -82.88 Max: -1.44
Current: -1.44
-31624.44
-1.44
Net-margin (%) 12.50
OPK's Net-margin (%) is ranked higher than
73% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. OPK: 12.50 )
Ranked among companies with meaningful Net-margin (%) only.
OPK' s Net-margin (%) Range Over the Past 10 Years
Min: -31688.9  Med: -118.52 Max: 12.5
Current: 12.5
-31688.9
12.5
ROE (%) 7.58
OPK's ROE (%) is ranked higher than
52% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.03 vs. OPK: 7.58 )
Ranked among companies with meaningful ROE (%) only.
OPK' s ROE (%) Range Over the Past 10 Years
Min: -3196.93  Med: -21.01 Max: 7.58
Current: 7.58
-3196.93
7.58
ROA (%) 5.17
OPK's ROA (%) is ranked higher than
59% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. OPK: 5.17 )
Ranked among companies with meaningful ROA (%) only.
OPK' s ROA (%) Range Over the Past 10 Years
Min: -1352.71  Med: -13.92 Max: 5.17
Current: 5.17
-1352.71
5.17
ROC (Joel Greenblatt) (%) 19.71
OPK's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.38 vs. OPK: 19.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -130662.93  Med: -367.75 Max: 19.71
Current: 19.71
-130662.93
19.71
Revenue Growth (3Y)(%) 85.10
OPK's Revenue Growth (3Y)(%) is ranked higher than
96% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. OPK: 85.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OPK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -11.6 Max: 152
Current: 85.1
0
152
EBITDA Growth (3Y)(%) 27.70
OPK's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. OPK: 27.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.6  Med: 6.6 Max: 161.2
Current: 27.7
-74.6
161.2
EPS Growth (3Y)(%) -16.40
OPK's EPS Growth (3Y)(%) is ranked lower than
78% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. OPK: -16.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.4  Med: -1.6 Max: 152.4
Current: -16.4
-69.4
152.4
» OPK's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

OPK Guru Trades in Q3 2015

Chuck Royce 521,525 sh (New)
John Hussman 750,000 sh (New)
Mario Gabelli 169,900 sh (+1599.00%)
Ken Fisher 35,500 sh (+21.58%)
Joel Greenblatt Sold Out
Jim Simons Sold Out
George Soros Sold Out
Murray Stahl 94,118 sh (-2.78%)
Paul Tudor Jones 46,800 sh (-60.93%)
» More
Q4 2015

OPK Guru Trades in Q4 2015

George Soros 55,500 sh (New)
Joel Greenblatt 120,369 sh (New)
Ken Fisher 37,826 sh (+6.55%)
Chuck Royce Sold Out
John Hussman Sold Out
Mario Gabelli 144,775 sh (-14.79%)
Murray Stahl 79,624 sh (-15.40%)
Paul Tudor Jones 26,500 sh (-43.38%)
» More
Q1 2016

OPK Guru Trades in Q1 2016

Ken Fisher 37,867 sh (+0.11%)
Paul Tudor Jones Sold Out
George Soros Sold Out
Murray Stahl 67,206 sh (-15.60%)
Mario Gabelli 100,775 sh (-30.39%)
Joel Greenblatt 30,179 sh (-74.93%)
» More
Q2 2016

OPK Guru Trades in Q2 2016

Paul Tudor Jones 27,173 sh (New)
Joel Greenblatt 267,485 sh (+786.33%)
Ken Fisher 37,826 sh (-0.11%)
Murray Stahl 66,333 sh (-1.30%)
Mario Gabelli 97,050 sh (-3.70%)
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:HYPMY, OTCPK:IPSEY, NAS:ENDP, NYSE:TARO, OTCPK:ORINY, NAS:NBIX, OTCPK:SFOSF, OTCPK:MDABY, OTCPK:STDAF, NAS:AKRX, OTCPK:DNPUF, NAS:HZNP, NYSE:CTLT, OTCPK:INVVY, NAS:MDCO, NYSE:RDY, NAS:RDUS, NYSE:DPLO, NAS:IRWD, NYSE:MNK » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Opko Health Inc is a biopharmaceutical and diagnostics company. The Company is engaged in the research and development of pharmaceutical products and vaccines.

OPKO Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.

Top Ranked Articles about OPKO Health Inc

Weekly CEO Buys: Abbott Laboratories, GE, OPKO Health Recent insider buys from company CEOs
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys: Ryman Hospitality, OPKO Health, Actuant Corp. Recent insider buys from company CEOs
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight Stock purchases from QEP Resources, OPKO Health and Korn/Ferry International CEOs
According to GuruFocus Insider Data, these were the largest CEO buys during the past week. The overall trend of CEO buys is illustrated in the chart below: Read more...
Insider Buys of More Than $100,000: Opko Health Chairman purchases 16,000 shares in company
Opko Health Inc. (NASDAQ:OPK) CEO, Chairman and 10% owner Phillip Frost M.D. et al bought 16,000 shares on June 14 at a price of $9.01 per share. The total transaction amount was $144,160. Read more...
Weekly CEO Buys Highlights Citigroup, Opko, JMP Group, Tuesday Morning, Calamos lead list, according to GuruFocus Insider Data
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: FS Investment, Opko, Ambac, Calamos, Praxair These are the largest CEO buys during the past week, according to GuruFocus' Insider Data
These are the largest CEO buys during the past week, according to GuruFocus' Insider Data. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: GHL, OPK, DKL, ATI, PEB A look at recent insider buys from CEOs
According to GuruFocus Insider Data, these were the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: Box, Opko, Neonode, FS Investment, Celator Pharmaceuticals GuruFocus Insider Data identifies CEOs' largest buys in the past week.
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: CC, OPK, PX, PSG, JOY A roundup of recent insider buys
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEO buys is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 35.71
OPK's P/E(ttm) is ranked lower than
62% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.55 vs. OPK: 35.71 )
Ranked among companies with meaningful P/E(ttm) only.
OPK' s P/E(ttm) Range Over the Past 10 Years
Min: 31.75  Med: 59.35 Max: 421.67
Current: 35.71
31.75
421.67
Forward P/E 108.70
OPK's Forward P/E is ranked lower than
97% of the 65 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.89 vs. OPK: 108.70 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 35.71
OPK's PE(NRI) is ranked lower than
61% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.41 vs. OPK: 35.71 )
Ranked among companies with meaningful PE(NRI) only.
OPK' s PE(NRI) Range Over the Past 10 Years
Min: 31.75  Med: 58.46 Max: 253
Current: 35.71
31.75
253
Price/Owner Earnings (ttm) 85.12
OPK's Price/Owner Earnings (ttm) is ranked lower than
80% of the 279 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.58 vs. OPK: 85.12 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
OPK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 20.6  Med: 106.33 Max: 1760
Current: 85.12
20.6
1760
P/B 2.49
OPK's P/B is ranked higher than
58% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.04 vs. OPK: 2.49 )
Ranked among companies with meaningful P/B only.
OPK' s P/B Range Over the Past 10 Years
Min: 2.17  Med: 8.82 Max: 800
Current: 2.49
2.17
800
P/S 4.55
OPK's P/S is ranked lower than
65% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.78 vs. OPK: 4.55 )
Ranked among companies with meaningful P/S only.
OPK' s P/S Range Over the Past 10 Years
Min: 4.48  Med: 33.86 Max: 158.13
Current: 4.55
4.48
158.13
EV-to-EBIT 184.32
OPK's EV-to-EBIT is ranked lower than
97% of the 524 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.32 vs. OPK: 184.32 )
Ranked among companies with meaningful EV-to-EBIT only.
OPK' s EV-to-EBIT Range Over the Past 10 Years
Min: -121.5  Med: -31.5 Max: 203.7
Current: 184.32
-121.5
203.7
EV-to-EBITDA 46.04
OPK's EV-to-EBITDA is ranked lower than
84% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.57 vs. OPK: 46.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6  Med: -35.3 Max: 539.9
Current: 46.04
-146.6
539.9
PEG 0.71
OPK's PEG is ranked higher than
80% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. OPK: 0.71 )
Ranked among companies with meaningful PEG only.
OPK' s PEG Range Over the Past 10 Years
Min: 0  Med: 83.73 Max: 10097.6
Current: 0.71
0
10097.6
Current Ratio 1.80
OPK's Current Ratio is ranked lower than
63% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. OPK: 1.80 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 5.54 Max: 415
Current: 1.8
0.88
415
Quick Ratio 1.65
OPK's Quick Ratio is ranked lower than
54% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. OPK: 1.65 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 4.9 Max: 415
Current: 1.65
0.48
415
Days Inventory 26.19
OPK's Days Inventory is ranked higher than
92% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. OPK: 26.19 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 26.19  Med: 233.05 Max: 500.07
Current: 26.19
26.19
500.07
Days Sales Outstanding 72.97
OPK's Days Sales Outstanding is ranked higher than
53% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.29 vs. OPK: 72.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 163.64 Max: 727.85
Current: 72.97
38.86
727.85
Days Payable 43.58
OPK's Days Payable is ranked lower than
75% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.16 vs. OPK: 43.58 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 43.58  Med: 112.55 Max: 1499.3
Current: 43.58
43.58
1499.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -21.30
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 424 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. OPK: -21.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3  Med: -14.4 Max: 0.4
Current: -21.3
-146.3
0.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.42
OPK's Price/Projected FCF is ranked lower than
57% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. OPK: 3.42 )
Ranked among companies with meaningful Price/Projected FCF only.
OPK' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.04  Med: 10.65 Max: 78.89
Current: 3.42
3.04
78.89
Price/Median PS Value 0.14
OPK's Price/Median PS Value is ranked higher than
98% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. OPK: 0.14 )
Ranked among companies with meaningful Price/Median PS Value only.
OPK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 1.28 Max: 30
Current: 0.14
0.14
30
Earnings Yield (Greenblatt) (%) 0.59
OPK's Earnings Yield (Greenblatt) (%) is ranked lower than
68% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. OPK: 0.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 0.5 Max: 0.6
Current: 0.59
0.5
0.6

More Statistics

Revenue (TTM) (Mil) $1,067
EPS (TTM) $ 0.26
Beta1.91
Short Percentage of Float23.29%
52-Week Range $7.12 - 11.85
Shares Outstanding (Mil)550.38

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,262 1,438 1,971
EPS ($) 0.09 0.33 0.63
EPS w/o NRI ($) 0.09 0.33 0.63
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Aug 29 2016 
Weekly CEO Buys Highlight Aug 22 2016 
Weekly CEO Buys: Abbott Laboratories, GE, OPKO Health Jul 31 2016 
Weekly CEO Buys: Akamai, Restoration Hardware Jul 23 2016 
Weekly CEO Buys: Ryman Hospitality, OPKO Health, Actuant Corp. Jul 17 2016 
Getting to Know VBI Vaccines Jul 13 2016 
Weekly CEO Buys Highlight Jul 10 2016 
Insider Buys of More Than $100,000: Opko Health Jun 16 2016 
Weekly CEO Buys Highlights Mar 14 2016 
Weekly CEO Buys Highlights Jan 26 2016 

More From Other Websites
'Mad Money' Lightning Round: I Am Committed to Opko Health Aug 30 2016
Transition Therapeutics Shareholders Approve Acquisition by OPKO Health Aug 26 2016
Transition Therapeutics Shareholders Approve Acquisition by OPKO Health Aug 26 2016
OPKO Health, Inc. breached its 50 day moving average in a Bearish Manner : OPK-US : August 24, 2016 Aug 24 2016
OPKO Health Responds to Law Firm Notice of Investigation Aug 23 2016
OPKO Health Responds to Law Firm Notice of Investigation Aug 23 2016
ETF’s with exposure to OPKO Health, Inc. : August 23, 2016 Aug 23 2016
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating OPKO Health, Inc. for Potential... Aug 23 2016
MabVax Therapeutics Announces the Closing of its Public Offering Aug 22 2016
OPKO HEALTH, INC. Financials Aug 13 2016
ETF’s with exposure to OPKO Health, Inc. : August 12, 2016 Aug 12 2016
OPKO Health, Inc. :OPK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 Aug 11 2016
Myriad Genetics Stock Craters As Competition Surprises Wall Street Aug 10 2016
Cocrystal Pharma Announces Filing 2016 Second Quarter Financial Statements and Provides Company... Aug 10 2016
Cocrystal Pharma Announces Filing 2016 Second Quarter Financial Statements and Provides Company... Aug 10 2016
Opko Health (OPK) Stock Higher After Q2 Earnings Beat Aug 09 2016
Edited Transcript of OPK earnings conference call or presentation 8-Aug-16 8:30pm GMT Aug 08 2016
OPKO Health tops Street 2Q forecasts Aug 08 2016
OPKO Health tops Street 2Q forecasts Aug 08 2016
OPKO HEALTH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)